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Known as the causative agent of genital herpes, HSV-2 infection affects half a billion people 
worldwide. When HSV-2 infects a host cell, the virus uses the host cell nucleic acid and protein 
synthesis machinery to replicate and assemble new viral particles. HSV-2, as well as the 
numerous other herpesviruses, have been shown to synthesize numerous immune modulation 
proteins.  Some viral proteins work simultaneously to block interferon synthesis and its signaling 
effects.  Since interferon is a critical player in host innate immunity, this may alter the immune 
response of the host significantly, for example prevent a proper early, innate immune response 
to infection.  However, the HSV-2 UL24 mutant seems to fail in inhibiting IFN production.  The 
mutant was shown to be significantly attenuated for virulence in multiple animal models and also 
acted as an effective prophylactic vaccine in mammalian models.  The proposed project will 
attempt to elucidate the mechanism through which the HSV-2 UL-24 protein inhibits the IFN 
regulatory pathway.  Western blot and immunofluorescence microscopy of wild type and mutant 
infected cells will be used to observe potential differences in the expression of a critical host IFN 
regulatory protein, IRF3.  An intimate understanding of how HSV-2 inhibits IFN production and 
evades the innate immune response may introduce new considerations in the development of 
HSV-2 vaccine and antiviral therapies. 
 
 
